TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and treg function to identify and characterize t…
| Métrica | TRXB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | — | -30.9% | — |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
TRex Bio, Inc. cotiza a 14.01 USD y tiene una capitalización bursátil de $385M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud